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ABSTRACT 
As the number of cases of Alzheimer’s disease (AD) is constantly rising in all 
developed countries, the unmet medical need for a curative treatment continues to 
grow. Current drugs improve symptoms, but do not have profound disease-modifying 
effects. The generation and aggregation of β-amyloid peptides (Aβ), proteolytic 
derivatives of amyloid precursor protein (APP), is believed to play a key role in the 
onset and progression of AD. Consequently, inhibition of the major APP cleaving 
enzyme, BACE1 (β-site APP cleaving enzyme), is generally recognised as a 
promising therapeutic strategy and currently an active area of investigation. A wide 
variety of BACE1 inhibitors have been reported so far. Among them is Reticulon 3 
(RTN3), which was recently proposed to act as a natural cellular modulator of BACE1 
activity.  
This study focused particularly on the interaction between BACE1 and RTN3, aiming 
to reconstitute the original approach and confirm binding between the two proteins. 
When using a transiently transfected neuroblastoma cell line binding assays did not 
show the proposed interaction. In a different approach, representing a fundamental 
part of the project, RTN3 was successfully cloned and expressed recombinantly. A 
systematic method was devised to combine both protein purification and binding 
studies of RTN3 and BACE1.  
Surprisingly, my findings indicated that the proposed interaction cannot be 
reconstituted using recombinant proteins.  
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ZUSAMMENFASSUNG 
Mit steigender Prävalenz von Morbus Alzheimer in den Industrienationen wird auch 
die bisher erfolglose Suche nach einer effektiven Pharmakotherapie immer 
dringlicher. Gegenwärtig verfügbare Medikamente verbessern zwar die Symptomatik, 
haben jedoch keinerlei Auswirkungen auf das Fortschreiten der Krankheit. Eine 
allgemein anerkannte Schlüsselfunktion in der Alzheimer-Pathogenese nimmt dabei 
die Produktion und Aggregation des Amyloid-β (Aβ) Peptids ein, eines 
proteolytischen Derivats des Vorläufers Amyloid Precursor Protein (APP). Aus 
diesem Grund erscheint die Inhibition des APP spaltenden Enzyms, BACE1 (β-site 
APP cleaving enzyme), als eine aussichtsreiche Strategie in der Therapie der 
Krankheit und ist derzeit Gegenstand intensiver wissenschaftlicher Forschung. Eine 
Vielzahl an BACE1 Inhibitoren wurde bereits identifiziert. Unter ihnen auch Reticulon 
3 (RTN3), das erst kürzlich als zelleigener BACE1 Modulator vorgeschlagen wurde. 
In der vorliegenden Arbeit wurde die Interaktion zwischen BACE1 und RTN3 
untersucht, mit dem vorrangigen Ziel, die bereits publizierte Methode zu überprüfen, 
zu validieren und die postulierte Protein-Protein Bindung zu bestätigen. Im ersten 
Teil der Arbeit wurde mit einer humanen Neuroblastom-Zelllinie gearbeitet. Eine 
transiente Transfektion mit RTN3 und darauf folgende Interaktionsstudien brachten 
jedoch keine positiven Resultate. In einem alternativen Versuch wurde RTN3 in 
einen bakteriellen Vektor integriert und rekombinantes Protein exprimiert, mit dem 
die Interaktionsstudien durchgeführt wurden. Dabei wurde eine neue Methode 
entwickelt, um die Proteinaufreinigung mit Bindungsstudien zwischen RTN3 und 
BACE1 zu kombinieren.  
Allerdings konnte mit Hilfe des rekombinanten Systems die Interaktion zwischen den 
beiden Proteinen nicht bestätigt werden. 
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CHAPTER 1 
INTRODUCTION 
1.1. Alzheimer’s disease 
Alzheimer’s disease (AD) is the most common cause of neurodegenerative dementia 
in the elderly (Francis et al., 1999). With the increasing longevity of our population, 
AD is already approaching epidemic proportions (Brookmeyer et al., 2007) with no 
cure or preventative therapy yet available. AD is a progressive and ultimately 
terminal brain disorder characterised pathologically by extracellular deposits of -
amyloid plaques, intracellular formation of neurofibrillary tangles and neuronal loss.  
The rare form of familial Alzheimer’s disease (FAD) has been identified to have a 
genetic link. It is inherited in an autosomal dominant fashion. All cases known so far 
have an early onset (< 65 years), and as many as 50 percent are now known to be 
caused by defects in three genes located on three different chromosomes. However, 
the more common form is sporadic AD, where no obvious inheritance pattern is seen 
and which tends to occur later in life. 
1.2. Pathology & Causes of AD 
Despite extensive study the exact etiology of AD still remains to be identified. 
However, three major hypotheses have been proposed to clarify the cause of the 
disease. The cholinergic hypothesis postulates a connection between some of the 
cognitive impairments of AD and a disturbance in cerebral cholinergic 
neurotransmission. Support for this theory came in the mid-1970s with reports of 
extensive neocortical deficits in the enzyme responsible for the synthesis of 
acetylcholine, choline acetyltransferase (Davies et al., 1976; Perry et al., 1977). 
Subsequent studies confirmed a substantial presynaptic cholinergic deficit due to 
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reduced choline uptake (Rylett et al., 1983), acetylcholine release (Nilsson et al., 
1986) and loss of cholinergic neurons (Whitehouse et al., 1982). At this time research 
also suggested an emerging role of acetylcholine in learning and memory (Drachman 
et al., 1974). Considering these observations it was proposed that degeneration of 
cholinergic neurons and the associated loss of cholinergic neurotransmission in the 
cerebral cortex contributed significantly to the deterioration in cognitive function seen 
in AD patients (Bartus et al., 1982). This hypothesis marked the very beginning of 
systematic biochemical investigations into the mechanisms of AD. Although many 
studies have challenged the veracity of the cholinergic hypothesis as an explanation 
for AD in the past 20 years, the theory has led to the discovery of several treatment 
targets that are still valid. Cholinesterase inhibitors play an important role in 
therapeutic treatment nowadays, and even though they are not a curative treatment 
they do allow the alleviation of some clinical symptoms. 
The second hypothesis is linked to the intracellular deposition of 
hyperphosphorylated tau. According to the tau hypothesis cognitive impairment 
correlates with abnormal aggregation of tau, a microtubule-associated protein 
expressed in neurons which stabilises microtubules in the cell cytoskeleton. In AD 
patients, hyperphosphorylated tau accumulates as paired helical filaments (Goedert 
et al., 2006) that consecutively aggregate into neurofibrillary tangles inside nerve cell 
bodies (Goedert et al., 1991). These tangles tend to associate with amyloid plaques, 
cause the microtubules to disintegrate and later induce a complete breakdown of the 
cellular transport system (Iqbal et al., 2005). The malfunctions in biochemical 
communication between neurons typically precede the death of the cell. 
The amyloid hypothesis proposes an early and crucial role of Amyloid -peptide (A) 
in initiating the pathogenic cascade of AD. It argues that the neurodegenerative 
progression, as well as the development of neurofibrillary tangles, is a consequence 
of an imbalance between the production and clearance of A (Hardy & Selkoe, 2002; 
Annaert & De Strooper, 2002). Further details on A generation and function will be 
provided in section 1.4. An increase in A production enhances oligomerisation and 
leads to the formation of plaques, consequently inducing neurotransmitter deficiency 
and neuronal damage leading to cell death.  
Introduction | Genetics of AD 
 
 
3 
 
So far, no single pathological lesion can explain all of the hallmarks of AD. There 
have been major debates as to whether amyloid plaques or neurofibrillary tangles 
occur first in AD pathology (Selkoe, 2001). However, genetic and pathological 
evidence strongly supports the amyloid cascade hypothesis (Citron, 2004), which I 
will elaborate on in the following sections.  
Further to the presented major hypotheses a variety of additional explanatory models 
has been published so far. Several inflammatory processes, mitochondrial 
dysfunction, metabolic disturbances and alterations in Insulin signalling, the loss of 
calcium regulation and defects in the cholesterol metabolism have been suggested to 
be relevant in the progress of AD (Querfurth et al., 2010).  
1.3. Genetics of AD 
The vast majority of AD cases are sporadic with no apparent genetic linkage. 
However, the growing understanding of the underlying genetic principles has been 
essential in uncovering some of the cell and molecular processes leading to the 
disease state. Genetic investigations started in 1981, when Heston et al. observed a 
high incidence of AD-type neuropathology in patients suffering from Down’s 
syndrome (trisomy 21). A possible genetic link between AD and an abnormal gene or 
structural defect on chromosome 21 seemed logical. This was later confirmed when 
the gene encoding the amyloid precursor protein (APP) was isolated and mapped to 
chromosome 21 (Goldgaber et al., 1987; Kang et al., 1987; Robakis et al., 1987; 
Tanzi et al., 1987). In the following years several mutations were found in APP, 
accounting for approximately 5-20 % of published cases of early-onset FAD (Tanzi et 
al., 1992; Campion et al., 1996). Efforts were turned towards the identification of 
other genes involved, and in 1995, presenilin 1 and 2 (PS-1; PS-2) were reported as 
novel FAD related genes on chromosome 14 and 1, respectively (Sherrington et al. 
1995; Levy-Lahad et al., 1995). The majority of mutations discovered on both 
presenilins and APP have been shown to increase the ratio of cerebral A (Scheuner 
et al., 1996; Price et al., 1998), in particular the more fibrillogenic form of the peptide, 
A42 (Jarrett et al., 1993). To date, a total of 32 rare, autosomal-dominant mutations 
have been found in APP, 176 in PS-1 and 14 in PS-2 (http://www.molgen.ua.ac.be/ 
ADMutations/), assigning in particular PS-1 a major role in contributing to early-onset 
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AD risk. However, there is still no evidence that genetic variants of the presenilins are 
associated with increased late-onset AD susceptibility.  
A genetic model to explain late-onset AD (> 65 years) was devised, when Pericak-
Vance, in 1991, reported a significant genetic linkage to the gene encoding 
apolipoprotein E (APOE), an apoprotein enhancing proteolytic break-down of A. The 
polymorphism 4 was identified to represent a major risk factor for the development 
of late-onset AD (Schmechel et al., 1993; Strittmatter et al., 1993). However, it is not 
a determinant of the disease as at least a third of AD patients are ApoE4 negative 
and some ApoE4 homozygotes never develop the disease. 
1.4. A pathways & APP processing 
The Amyloid cascade hypothesis proposes an accumulation of A deposits as the 
initial cause for AD. A, between 39 to 43 amino acids in length, is formed after 
sequential cleavage of the amyloid precursor protein (APP). APP is a 
transmembrane glycoprotein of as yet undetermined function, which is ubiquitously 
expressed throughout the body (Ling et al., 2003) and can be processed by two 
major different pathways (Figure 1.1).  
The first pathway is the non-amyloidogenic -secretory pathway where APP is firstly 
cleaved by -secretase to produce soluble sAPP and the carboxy-terminal 
fragment, C83. This membrane embedded C83 fragment is further cleaved 
intramembranously by -secretase, releasing the non-pathogenic p3 peptide into the 
extracellular space.  
Alternatively, APP cleavage can occur via the pathological amyloidogenic -secretory 
pathway. Here, initial cleavage is catalysed by -secretase, resulting in the release of 
the sAPP fragment and leaving the membrane-bound C-terminal fragment C99. The 
C99 domain is cleaved within the cell membrane by -secretase to create pathogenic 
A (De Strooper & Annaert, 2000; Koo, 2002) and AlCD. There are two major forms 
of A: the more abundant and soluble 40 amino acid fragment and the pathogenic 42 
amino acid isoform, A42 (Jarrett et al., 1993). AICD is released into the cytoplasm 
and targeted to the nucleus, signalling transcription activation. 
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Figure 1.1: Processing of Amyloid Precursor Protein. 
In the -secretory pathway APP is cleaved by -secretase and γ-secretase to form sAPP, 
AICD and the non-pathogenic P3. In the β-secretory pathway APP is processed by β-
secretase (BACE1) and γ-secretase to produce sAPPβ, AICD and amyloid plaque-causing 
Aβ. Lipid rafts are membrane micro-environments enriched in sphingomylelin, cholesterol, 
and glycophosphatidylinositol (GPI)–anchored proteins. They play a major role in the 
assembly of β- and γ-secretases and the processing of APP into Aβ.  
(Figure according to Querfurth et al., 2010) 
 
1.5. AD associated secretases 
-secretase 
Several proteins with -secretase-like activity have been identified to date (Ling et 
al., 2003; Dillen & Annaert, 2006). The majority of candidates belong to the ADAM (“a 
disintegrin and metalloproteinase domain”) family. Those expected to be of relevance 
in AD are the two metalloproteinases ADAM10 and ADAM17 (TACE) which have 
been shown to act as -secretases (Allinson et al., 2003). Another protease that may 
cleave APP at the -secretase site is BACE2 (-site APP-cleaving enzyme 2), a 
homologue of the -secretase enzyme BACE1. However, the function of BACE2 as 
either an - (Yan et al., 2001; Basi et al., 2003) or -secretase (Hussein et al., 2000; 
Yan et al., 1999) has not yet been fully defined. Furthermore, low levels of 
expression in the brain suggest it might play a rather unimportant role (Vassar et al., 
2002).  
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-secretase 
The -secretase intramembraneous protease complex is responsible for the final 
cleavage of APP resulting in the release of p3 peptide or A. The complex is 
composed of 4 individual proteins: presenilin (PS), nicastrin (NCT), anterior pharynx-
defective 1 (APH-1) and presenilin enhancer 2 (PEN-2). PS is an aspartyl protease 
and the catalytic subunit of -secretase. Kaether et al., in 2006, developed a model of 
complex assembly in which NCT and APH-1 stabilise PS before PEN-2 is added as 
the last component to complete the complex. PEN-2, among other possible roles, 
helps to stabilise the complex after PS proteolysis has generated the activated N- 
and C-terminal fragments of APP (Prokop et al., 2004).   
-secretase 
Proteolytic processing of APP at the -site is essential in the generation of A. The 
major -secretase in the brain is a type 1 membrane-associated aspartyl protease of 
501 amino acids, called -site APP-cleaving enzyme 1 (BACE1; Hussain et al., 1999; 
Sinha et al., 1999; Vassar et al., 1999; Yan et al., 1999). Like many other proteases, 
BACE1 is produced as a pro-enzyme predominantly within the endoplasmic reticulum 
(ER) and the nuclear envelope and is trafficked through the Golgi to the cell surface 
during which it is post-translationally modified. The mature enzyme exhibits complex 
N-glycosylation and three intramolecular disulfide-bonds, which are critical but not 
essential for APP processing (Fischer et al., 2002). Three cysteine residues within 
the cytosolic tail of BACE1 are palmitoylated, which may influence intracellular 
localisation or trafficking (Benjannet et al., 2001).  
BACE1 is the rate-limiting enzyme in the formation of A (Vassar, 2001). Over-
production of BACE1 in cell cultures enhanced the quantity of -secretase cleavage 
products (Vassar et al., 1999). More importantly, a transgenic mouse line expressing 
human BACE1 induced the amyloidogenic processing of APP and elevated A42 
levels (Bodendorf et al., 2002). Knocking out the BACE1 gene completely impaired 
the -secretase cleavage of APP and diminished the production of A (Cai et al., 
2001). Surprisingly, BACE1 deficient mice developed normally and showed no 
phenotypic alterations despite an abolished -secretase activity in the brain (Luo et 
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al., 2001; Roberds et al., 2001). This indicates that BACE1 might be dispensable for 
normal development and physiological functions in vivo. Moreover, elevated BACE1 
has been observed in the brains of individuals with sporadic AD (Holsinger et al., 
2002; Fukumoto et al., 2002; Yang et al., 2003). The inhibition of BACE1 activity 
therefore seems to be a promising therapeutic strategy in the treatment of AD 
(Citron, 2004).  
 
Figure 1.2: Sequence organisation of β-secretase.  
BACE1 has a cleaved signal peptide, a prodomain and a catalytic domain which contains the 
catalytic aspartic residues. The catalytic domain comprises 3 di-sulfide bridges which is 
characteristic for aspartic proteinases and is glycosylated at 4 sites. The cytoplasmic tail 
contains a di-leucine endosomal retreival signal, palmitoylated cysteine residues and 
phosphorylation sites. (Colin Dingwall, 2001: Spotlight on BACE) 
1.6. Reticulons as BACE1 inhibitors 
The concept of -secretase inhibition seems to be a promising line of inquiry in the 
treatment of AD. However, inhibitor development has proved challenging. For 
aspartic proteases, potent and specific peptidic inhibitors can usually be identified, 
but the transition to small drug-like molecules with the desired pharmacokinetics and 
the ability to penetrate the blood-brain-barrier remains difficult (Vassar, 2002). Over 
the past few years a wide variety of BACE1 inhibitors have been reported, many of 
them were designed as peptidomimetic inhibitors based on transition-state analogues 
(Kimura et al., 2006).  
An alternative approach to inhibit BACE1 was the identification of natural cellular 
modulators of BACE1 activity. For instance, it has been demonstrated that BACE1 
activity is regulated by the level of glycosylation (Charlwood et al., 2001), 
composition of lipids in the membrane bilayer (Kalvodova et al., 2005), interactions 
with heparin sulphate (Scholefield et al., 2003) and, more recently, the reticulon 
proteins. In 2004, He et al. used a coimmunoprecipitation approach to search for 
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cellular proteins that interact with BACE1 and reported the identification of reticulon 
family members as binding partners and inhibitors of BACE1.  
Reticulons (RTNs) are a group of integral membrane proteins that are largely 
localised in the endoplasmatic reticulum (ER) and exist in plants, fungi and animals 
(Oertle et al., 2003a). While the precise cellular functions remain to be defined, RTNs 
have been shown to regulate many different cellular processes. They have also been 
demonstrated to interact with diverse cellular proteins, extracellular receptors 
(Fournier et al., 2001), fusion and endocytic proteins (Oertle et al., 2003a). In 
mammalian genomes, four independent reticulon genes - RTN1, RTN2, RTN3 and 
RTN4 - have been identified to encode a large number of gene products with multiple 
spliced variants. While the exact functions of RTN1 to RTN3 are unknown, research 
has revealed a significant role of RTN4, also known as Nogo, in regulatory processes 
in the mammalian central nervous system. The subform RTN4-A has been shown to 
inhibit neurite outgrowth and cell spreading in vitro (Oertle et al., 2003b), preventing 
the regeneration of lesioned nerve fibers in the brain (Chen et al., 2000). 
All RTNs are composed of a completely divergent N-terminal domain, and a highly 
conserved RTN homology domain (RHD), unique to this family of proteins (Yang and 
Strittmatter, 2007). The conservation of the RHD has already been shown to confer 
common functions upon RTNs, such as localising RTNs to the appropriate 
membranes and/or mediating protein interactions (Yan et al., 2006). As previously 
mentioned all RTN members were shown to interact with BACE1, implying that the 
conserved RHD may mediate binding of RTNs to BACE1. This study focused in 
particular on RTN3 because of its strong inhibitory effects on enzyme activity and 
high expression by neurons (He et al., 2004). 
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1.7. RTN3: structural organisation and binding to BACE1 
Among all reticulon family members RTN3 showed the highest expression in mouse 
and human post-mortem brain. In the latter it was predominantly expressed in gray 
matter and enriched in neuronal cell bodies. It is localised primarily in the ER and the 
Golgi (He et al., 2004; Wakana et al., 2005). However, it was also found in axons, 
dendrites, and the growth cone (Hu et al., 2007). BACE1, although being ubiquitously 
present in all brain regions, shows a substantially higher expression in neurons 
(Vassar et al., 1999), similar to RTN3. All this data indicates that RTN3 is more likely 
to be related to A production in human brain than other RTN members. On a cellular 
level, interaction is expected to take place in both the ER and Golgi or Trans-golgi-
network (TGN) compartments, as both proteins have been successfully co-localised 
there (He et al., 2004).  
 
 
 
Figure 1.3: Structural organisation of RTN3.  
A schematic diagram of full-length RTN3 (236 aa), showing transmembrane regions (TM), 
whereas TM1 governs insertion of RTN3 into the membrane, the loop and C-terminal tail. 
Below is the predicted membrane topology of RTN3. All figures according to He et al., 2007. 
As illustrated in figure 1.3 RTN3 adopts a ω-shape membrane topology with both the 
N- and C-terminal ends retained on the cytosolic side. Like other members of the 
reticulon family RTN3 has two major domains: an unique N-terminal domain (NTD) 
and the C-terminal RHD. The latter includes two long hydrophobic stretches (28-36 
amino acids) that are separated by a 66 amino acid loop, and a C-terminal tail. The 
two putative transmembrane (TM) domains embed RTN3 in the membrane and have 
been shown to be critical components for the function of RTNs. Disruption of the TM1 
domain prevents integration of RTN3 into the membrane, suggesting that proteins 
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are perhaps misfolded and degraded in cells. RTN3 mutants with disruption or 
deletion in either TM1 or TM2 also fail to interact with BACE1 as the binding domain 
is probably buried due to different protein folding (He et al., 2007).  
The exact region mediating the binding of RTN proteins to BACE1 has been mapped 
to the C-terminal tail, in particular a highly conserved triplet amino acid QID motive 
that is shared among all RTN members (He et al., 2006). According to these 
observations proper integration of RTN3 into the lipid bilayer as well as optimal 
conformation of transmembrane regions and the C-terminal tail containing the 
conserved QID motive are essential for the binding of RTN3 to BACE1.  
From the BACE1 perspective binding is mediated by the C-terminal region, with 
those sequences immediately adjacent to the transmembrane domain (TM) being of 
substantial importance for successful interaction. The topological orientation is 
consistent with the location of the RTN3 QID motif. Both regions face the cytoplasmic 
side, allowing direct contact. Similar to the observations made for RTN3, the 
appropriate orientation of BACE1 within the membrane seems to be important, 
although the BACE1 TM alone is insufficient for interaction with RTN3 (He et al., 
2006).  
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CHAPTER 2 
AIMS AND OBJECTIVES 
BACE1 is widely recognised to be one of the most promising drug targets for 
inhibition of A generation. Various approaches for inhibiting BACE1 have already 
been actively pursued and the identification of RTN3 as a BACE1 modulator offers 
an alternative possibility to discover small molecules that could mimic inhibitory 
effects. To study this potential regulatory mechanism in molecular detail it is essential 
to establish a method to reconstitute the BACE1-RTN3 binding in vitro. 
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CHAPTER 3 
MATERIALS & METHODS 
3.1. Materials & Chemicals  
All chemicals were purchased from Sigma-Aldrich Ltd (Poole, UK) unless stated 
otherwise.  
3.2. Cell Culture 
3.2.1. Cells  
The cells used in this study were stably transfected SH-SY5Y cells. SH-SY5Y (5Y°) 
is a human neuroblastoma cell line and was purchased from ATCC. The BACE1-
MYC vector (C-terminally tagged) was prepared by Emma Gray at the Institute of 
Psychiatry (King’s College, London) and the stable cell line was created by Dr Ruth 
Rose (King's College, London). 
3.2.2. Solutions  
All solutions mentioned in this section were purchased from Invitrogen unless stated 
otherwise.  
 Medium 
Dulbecco's Modified Eagle Media (DMEM), supplemented with 
Fetal Bovine Serum (FBS) 10 % 
Glutamine 2 mM 
G418 2 mM 
 Trypsin/EDTA 10x 
Trypsin 0.25 %  
EDTA 0.53 mM  
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3.2.3. Propagation and splitting of cells 
Cells were cultured in T-75 flasks at 37 °C with 95 % air, 95 % humidity and 5 % CO2. 
Once a cell-confluency between 80 to 90 % was reached, the culture was split in 
order to achieve continuous growth. The medium was removed from the T-75 flask 
using a vacuum aspirator and 5 ml of 10x Trypsin/EDTA was added to detach 
adherent cells from the flask surface. Remaining cells were detached by knocking. 
After 5 minutes incubation at 37 °C 1 ml of FBS was added to stop Trypsin/EDTA 
from acting on the cells. The cells were pelleted by centrifugation at 2,000 rpm for 5 
minutes. The supernatant was aspirated and the cells resuspended in 5 ml of 
medium. A 1 ml aliquot was removed and pipetted into a new T-75 flask containing 
10 ml of medium. The remaining 4 ml of suspension were, if needed, used to grow 
larger cultures in T-175 flasks along with 15 ml of medium. Cells were regularly 
observed under a microscope to control appropriate growth. 
3.2.4. Harvesting cells (T-175) 
Fully confluent T-175 cells were harvested with 10 ml of Trypsin/EDTA and after 5 
minutes 2 ml of FBS as described in section 3.2.3. The cells were pelleted by 
centrifugation at 2,000 rpm for 5 minutes; the pellet was resuspended in 1 ml of 
sterile PBS (Sigma) and then pelleted again. After aspirating the supernatant the 
pellet was frozen at -80 °C for storage. 
3.2.5. Counting cells  
To seed an accurate number of cells into a multi-well the cells were harvested with 
Trypsin/EDTA and FBS as described in section 3.2.3. Cells were pelleted and 
resuspended in 1 ml of medium. A 10 µl aliquot of the suspension was added to 40 µl 
of 0.02 % Trypan Blue plus 30 µl PBS in a micro-centrifuge tube. A 10 µl sample of 
this mixture was directly applied to a haemocytometer. Cells were counted and the 
concentration of cells in suspension was calculated according to equation 3.1, 
whereby 8 is the dilution factor and 104 is the area coefficient. 
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3.2.6. Transfection 
5Yo cells overproducing BACE1-MYC were counted as described in section 3.2.5, 
seeded at a density of 2 x 105 cells per well in a 6-well-plate and allowed to grow for 
18 hours. In a 1.5 ml micro-centrifuge tube 2 µg of isolated double-stranded plasmid 
DNA (received from Dr Mitsuo Tagaya, Department of Pharmacy & Life Science at 
Tokyo University) was suspended in 100 µl of Opti-MEM®. A solution of 10 % 
Lipofectamine™ in Opti-MEM® was prepared and 100 µl was added to the DNA- 
Opti-MEM®-mix in the tube. The mixture was flicked gently and incubated at room 
temperature for 45 minutes. A further 200 µl of Opti-MEM® was added. The medium 
in the 6-well-plate was removed and to each well 0.4 ml of DMEM and 0.4 ml of DNA- 
Opti-MEM® mixture were added. The plate was incubated at 37 °C for 6 hours in an 
incubator. The culture was provided with additional 0.8 ml of medium containing 10 
% extra FBS (20 % in total) and left for another 3 days in the incubator to grow. 
3.3. Molecular Biology Methods  
All general nucleic acid protocols were carried out as described in Laboratory 
Manuals (Sambrook et al. 2001). 
3.3.1. Materials 
Bacterial strains 
Strains Genotype Description Source 
JM109 endA1, recA1, gyrA96, 
thi, hsdR17 (rk-, mk+), 
relA1, supE44, Δ(lac-
proAB), F’, traD36, 
proAB, laqIqZΔM15 
Lac promoter Promega 
BL21-Codonplus(DE3)-RIL E. coli B F
– ompT 
hsdS(rB
– mB
–) dcm+ Tetr 
gal λ(DE3) endA Hte 
[argU ileY leuW Camr] 
IPTG inducible, 
T7 promoter 
Stratagene 
Table 3.1. The complete list of bacterial E.coli strains used during this study. 
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Plasmids 
Plasmids carrying the BACE1 gene (pGEX-4T-1-BACE1, amino acids 477-501) were 
constructed by Dr B. Angeletti as described in Angeletti et al. (2005) 
Vector Description Source 
pMal-c2x Over-expression maltose-binding protein 
(MBP) fusion vector, AmpR, lac promoter 
NEB 
pCW01 pMal-c2x containing MBP-fused RTN3 HD 
cloned, BamHI, HindIII 
this study 
pGEX-4T-1 High level expression Glutathione-S-
transferase (GST) fusion vector, tac 
promoter, lac Iq, AmpR 
GE Healthcare 
pBA9-pGEX-4T-1 GST-fusion vector, containing the 
sequence coding for BACE1 amino acids 
477-501 
Dr B. Angelleti 
Table 3.2. The complete list of vectors used during this study.  
Solutions 
 Tris-EDTA (TE) Buffer 
10 µM Tris-HCl pH 8.0 
1 mM EDTA pH 8.0 
Autoclaved 
Bioinformatics 
The amino acid sequence for RTN3 was obtained from the NCBI website 
(http://www.ncbi.nlm.nih.gov/). NEBCutter v2.0 (http://tools.neb.com/NEBcutter2) was 
used to visualise the open reading frames of the DNA sequences and select 
appropriate restriction enzyme sites. MultAlin was used to generate sequence 
alignments (http://bioinfo.genotoul.fr/multalin/multalin.html.) 
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3.3.2. Polymerase Chain Reaction 
The PCR was carried out in a 2720 Thermal cycler (Applied Biosystems, USA). All 
solutions and buffers were purchased from Invitrogen unless stated otherwise. 
3.3.2.1. PCR for DNA Amplification 
According to the instruction manual for Platinum® Taq Polymerase (Invitrogen) all 
reagents were prepared in a sterile PCR tube as stated in Table 3.3 and gently 
flicked. 
Reagent Volume (µl) 
10x PCR Reaction Buffer Minus Mg2+ 5 
10 mM dNTPs 1 
50 mM MgCl2 1.5 
10 µm 5’ primer 1 
10 µm 3’ primer 1 
ddH2O 39.3 
Template DNA 1 
Platinum® Taq DNA Polymerase 0.2 
Table 3.3. Components used for DNA Amplification. 
The reaction took place under the following conditions: 
PCR Method 1 cycle  activation 2 mins  94°C 
 35 cycles  denaturing 30 sec 94°C 
 annealing  30 sec  53°c  
 elongation 10 sec 72°C  
 4°C store overnight 
The complete pFLAG-RTN3-CMV-6c template was received from Dr Mitsuo Tagaya 
at Tokyo University, Department of Pharmacy & Life Science. The Primers were 
designed to replicate the C-terminal homology domain of RTN3 (RTN3 HD). 
Restriction sites for BamHI and HindIII were incorporated into the primers (Table 3.4) 
to allow the gene to be inserted into the multiple cloning site of the pMal-c2x vector 
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(Table 3.2). All primers used in this study were purchased from Invitrogen (Paisley, 
UK), prepared at a stock conc of 100 µM in TE and diluted to 10 µM in TE for use. 
Reaction products were analysed by agarose gel electrophoresis (section 3.3.3). 
Source 5’ / 3’ Primer sequence Restriction site 
RTN3 HD 5’ 
CTG GAT CCT ATG AGA AGT ACA AGA 
CCC 
BamHI 
RTN3 HD 3’ CCA AGC TTC CAT GTA CTT ATT CTG CC HindIII 
Table 3.4. Primers used in this study. The forward primer incorporated two additional 
residues to maintain the reading frame, the BamHI restriction site and 19bp of template 
RTN3 HD annealing sequence. The reverse primer contained two residues, the HindIII 
restriction site and 18bp of template RTN3 HD annealing sequence. 
3.3.2.2. Colony PCR 
Colony PCR was used to determine whether transformed colonies carried the 
desired gene. Colonies on the plate were numbered 1-10, stabbed with a 10 µl 
pipette tip and resuspended in 10 µl of sterile water. A 1 µl aliquot of resuspended 
colony was added to 9 µl of the PCR Stock Mix (Table 3.5) and the PCR performed 
as described in section 3.3.2.1. The remaining suspension was stored at -20 °C. A 
negative control containing only the vector pMal-c2x was prepared the same way. 
The PCR products were run on a 1 % agarose gel as described in section 3.3.3 and 
colonies carrying the plasmid with insert were identified by the formation of a 139 bp 
band, representing the amplified RTN3 HD.  
Reagent Volume (µl) 
5x Green GoTaq® Flexi Buffer (Promega) 2 
25 mM MgCl2 (Promega) 0.6 
10 mM dNTPs 0.2 
10 µm 5’ primer 0.4 
10 µm 3’ primer 0.4 
ddH2O 5.4 
GoTaq® Flexi DNA Polymerase (Promega) 0.05 
Table 3.5. 1x PCR Stock Mix for 31 Colony PCR Reactions. 
Materials & Methods | Molecular Biology Methods 
 
 
19 
 
3.3.3. Agarose Gel Electrophoresis 
Agarose gel electrophoresis was performed to isolate and identify DNA fragments. A 
1 % agarose gel was used throughout all studies due to the high resolution of DNA 
fragments within the desired molecular weight range (0.5 - 7 kb). After an electrical 
current was applied, negatively charged DNA migrated towards the anode, 
transporting smaller molecules considerably faster through the polysaccharide matrix 
and thus separating DNA molecules by size. 
Nucleic acids were visualised in the gel by addition of the fluorescent dye ethidium 
bromide, which intercalates between the bases of the DNA strand. The DNA-dye 
complex absorbs UV light and emits visible orange light at 590 nm which was 
observed on an ultraviolet transilluminator. Images were taken using the Syngene 
Bioimaging System UP-D895. 
Methodology 
A 1 % agarose gel was prepared by dissolving Agarose (Amresco) in 1x UltraPure™ 
TAE buffer (Invitrogen). Ethidium bromide was added to a concentration of 0.5 µg/ml 
and the liquid gel was poured into a casting tray containing a sample comb and left to 
set evenly. After the gel had solidified, the comb was removed and the gel, still in the 
tray, was inserted horizontally into the electrophoresis chamber and submerged in 1x 
TAE Buffer. DNA samples were mixed with DNA loading dye (Promega) and loaded 
onto the gel. A 100 bp marker (Promega) was used as a reference (Figure 3.1). The 
gel was run at a current of 95 Volts for 40 minutes and visualised under ultraviolet 
light (254 nm, high energy). 
 
Figure 3.1. 100bp DNA molecular weight marker (Promega). 
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3.3.4. Gel Extraction 
To purify the DNA from an agarose gel the QIAquick® Gel Extraction Kit (QIAGEN 
GmbH) was used. The extraction was completed following the method outlined in the 
QIAquick® Gel Extraction Kit protocol for micro-centrifuge. The DNA was eluted in 50 
µl of Buffer EB into a sterile 1.5 ml micro-centrifuge tube and stored at -20°C. 
3.3.5. Restriction Digests 
All restriction enzymes and buffers employed here were purchased from Promega. 
3.3.5.1. Large scale digests 
To digest large quantities of DNA a restriction digest was set up as stated below 
(Table 3.6). The mixture was incubated at 37 °C for 3 hours to ensure complete 
digestion. 
Reagent Volume (µl) 
Extracted DNA 15 
ddH2O 10 
BamHI 1 
HindIII 1 
Buffer E (Promega) 3 
Table 3.6. Components used for large scale digests.  
3.3.5.2. Analytical digests 
Samples were prepared at the concentrations and with the optimal buffer selected 
according to the manufacturer’s instructions (Table 3.7). The digest was left to 
incubate at 37 °C for 1 hour and run on a 1 % agarose gel (section 3.3.3).  
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Reagent Volume (µl) 
DNA miniprep/ pMal-c2x 4 
Restriction enzyme 0.5 
Buffer 1 
ddH2O 4 
Table 3.7. Components used for analytical digests. 
3.3.6. DNA Clean-Up 
DNA fragments were purified using Qiagen’s QIAquick® PCR Purification Kit 
Protocol for a micro-centrifuge. The DNA was eluted in 30 µl of Buffer EB into a 1.5 
ml micro-centrifuge tube.  
3.3.7. Ligation 
Digested DNA fragments were ligated using T4 DNA Ligase as stated below (Table 
3.8).  The ligation product was stored overnight at 4 °C. 
Reagent Volume (µl) 
2x T4 DNA ligase buffer (Promega) 5 
T4 DNA ligase (Promega) 0.5 
pMal-c2x digested with BamHI, HindIII (vector) 2 
Digested DNA fragment (insert) 2.5 
Table 3.8. Components used for ligation. 
3.3.8. Transformation 
Competent cells, BL21-Codonplus(DE3)-RIL, were slowly defrosted on ice. A 
maximum volume of 10 % ligation product (for a complete list of all plasmids used 
see Table 3.2) was added to the cells, mixed carefully and left to stand on ice for 15 
minutes. The cells were heat shocked for 50 seconds at 42 °C to ensure the uptake 
of genetic material and immediately placed on ice for 2 minutes. An aliquot of 200 µl 
LB was added and cells were allowed to replicate at 37 °C for 1 hour, giving them 
enough time to produce the newly acquired antibiotic resistance. Cells were spread 
onto LB-agar plates, containing the required antibiotics, and incubated overnight at 
37 °C. 
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3.3.9. Miniprep 
Starter cultures containing 5 ml of LB, antibiotics where required, and a single colony 
were grown overnight at 37 °C, whilst shaking. The cells were pelleted by 
centrifugation at 4,000 rpm for 20 minutes at 4 °C. To extract the plasmid DNA from 
the pellet the QIAquick® miniprep kit for micro-centrifuge (Qiagen GmbH) was used. 
The DNA was eluted in 50 µl of EB buffer and stored at -20 °C. 
3.4. Microbiological Methods 
3.4.1. Media for microbiological growth 
Tryptone and yeast extracts were purchased from Oxoid Ltd., Hampshire, England. 
Sources of other materials are stated in the text. 
 Luria Bertani Broth (LB) 
NaCl    5 g/L 
Yeast extracts  5 g/L 
Tryptone   10 g/L 
Autoclaved 
 LB agar 
Agar in LB   15 g/L 
Autoclaved 
 Ampicillin 
10 µg/ml in dH2O 
Filter sterilised and stored at -20 °C 
 Chloramphenicol 
34 µg/ml in 99 % Ethanol 
Stored at -20 °C 
 Isopropyl -D-1-thiogalactopyranoside (IPTG) 
0.4 mM in dH2O 
Filter sterilised and stored at -20 °C 
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3.4.2. Production of Recombinant Proteins 
The E.coli strain BL21-Codonplus(DE3)-RIL was transformed (section 3.3.8) with an 
expression plasmid carrying the desired gene (Table 3.2) and incubated at 37 °C 
overnight on a LB plate with the required antibiotics. Starter cultures were prepared 
containing 5 ml of LB, the required antibiotics and a colony from each LB plate. 
Following 4 hour incubation at 37 °C on a shaker, 1 starter culture was used to 
inoculate 0.5 L of LB which was again cultivated at 37 °C, whilst shaking, until an A600 
of 0.6-0.8 was reached. Protein production was induced by adding IPTG (Promega) 
and the cultures were incubated overnight at 17 °C, shaking. 
3.4.3. Harvesting the Recombinant Proteins 
Cells were pelleted by centrifugation at 4,000 rpm for 20 minutes at 4 °C. The 
supernatant was removed and the remaining pellet was resuspended in 5 ml of 50 
mM Tris-HCl pH 7.4, 100 mM NaCl and stored at -20 °C until use. 
3.4.4. Small scale growth experiment 
Optimal growth conditions were evaluated in a small scale growth trial. Small scale 
bacterial cultures (20 ml) were incubated at 37 °C until an A600 of 0.6-0.8 was 
obtained and then induced by the addition of IPTG. The cells were either maintained 
at 37 °C or transferred to 17 °C and kept shaking. The first set of cells at 17 °C and 
37 °C was harvested after 2 hours (section 3.4.3). The two remaining cultures were 
left to grow overnight. 
3.5. Protein Biochemistry Methods 
3.5.1. Cell lysis 
3.5.1.1. Cell lysis by detergent 
Solutions 
 Lysis Buffer  
Tris pH 8.3  50 mM  
NaCl   150 mM  
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Triton X-100 0.1 % 
Protein inhibitor cocktail without EDTA (Roche) 
5Y° cells overproducing BACE1-MYC were transiently transfected with FLAG-RTN3 
and cultured in 6-well-plates (section 3.2.6). The medium was aspirated and each 
well was washed with 1 ml PBS. The cells were lysed in 100 µl of lysis buffer, 
incubated on ice for 20 minutes and finally observed under a microscope to ensure 
complete lysis. The lysate was transferred into 1.5 ml micro-centrifuge tubes and 
pelleted by centrifugation for 30 minutes at 4 °C to remove cell residue. The 
supernatant containing the isolated protein was collected in 1.5 ml tubes. 
Alternatively, for displaying BACE-MYC only, 5Y° cells were harvested as stated in 
section 3.2.4 and T-175 cell pellets were used for cell lysis. 
3.5.1.2. Cell lysis by sonication 
Recombinant bacteria grown and harvested as described in section 3.4.2 and 3.4.3 
were lysed by sonication using a Sonics Vibracell Ultrasonic Processor. The samples 
were sonicated for 10 cycles of 30 seconds at 60 % amplitude and maintained on ice 
throughout. Lysed cells were pelleted by centrifugation (Beckman JA20 rotor) at 
14,000 rpm at 4 °C for 20 minutes. The supernatant and pellet were collected in 
separate fractions. The pellet was resuspended in 5 ml of 50 mM Tris-HCl pH 7.4 and 
100 mM NaCl. 
3.5.2. Protein Purification 
3.5.2.1. Individual Purification by MBP Affinity Column 
Solutions 
 Maltose Column Buffer  
Tris-HCl pH 7.4  20 mM 
NaCl  200 mM 
EDTA  1 mM 
  
Materials & Methods | Protein Biochemistry Methods 
 
 
25 
 
 Maltose Column Elution Buffer  
Tris-HCl pH 7.4  20 mM 
NaCl  200 mM 
EDTA  1 mM 
Maltose  10 mM 
Methodology  
In order to purify recombinant MBP-RTN3 HD individually a MBP affinity column was 
employed. Recombinant protein was produced in the E.coli strain BL21-
Codonplus(DE3)-RIL (section 3.4.2), harvested (section 3.4.3) and lysed by 
sonication (section 3.5.1.2). Cell debris was pelleted by centrifugation at 14,000 rpm 
and 4 °C for 20 minutes. The supernatant containing MBP-tagged protein was 
applied to an amylose column (NEB) pre-equilibrated in 30 ml of maltose column 
buffer. The column was washed with 50 ml of maltose column buffer to remove non-
specific protein and column-bound protein was eluted with elution buffer.  
3.5.2.2. Individual Purification by GST Sepharose Column 
Solutions  
 Column Buffer (1x PBS) pH 7.4 
NaCl  140 mM 
KCl  2.7 mM 
Na2HPO4 10 mM 
KH2PO4 1.8 mM 
 Glutathione Elution Buffer  
Reduced Glutathione  10 mM 
Tris-HCl pH 8.0 50 mM 
Methodology  
Recombinant proteins GST-BACE1 or GST were individually purified using a 
Glutathione Sepharose 4B column (GE Healthcare). Recombinant protein was 
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produced in the E. coli strain BL21-Codonplus(DE3)-RIL (section 3.4.2), harvested 
(section 3.4.3) and lysed by sonication (section 3.5.1.2). Cell debris was pelleted and 
the supernatant containing GST-tagged protein applied to the column pre-
equilibrated in 30 ml of column buffer. The column was washed with 50 ml of buffer 
and resin-bound protein was eluted with glutathione elution buffer.  
3.5.2.3. Dual-Purification of two proteins using a MBP Affinity Column 
The aim of this method was to purify two interacting proteins using the same affinity 
column. Recombinant protein was produced (section 3.4.2), harvested (section 3.4.3) 
and lysed by sonication (section 3.5.1.2). Cell debris was pelleted and the 
supernatant containing MBP-tagged protein applied to an amylose column pre-
equilibrated in 30 ml of maltose column buffer. The column was washed with 50 ml of 
maltose column buffer to remove non-specifically bound protein. The supernatant of 
the second recombinant protein was diluted 1:3 with column buffer and applied to the 
column. The column was washed with column buffer and any protein bound to the 
resin was retrieved by the addition of maltose column elution buffer. The elution 
fractions were collected in 1.5 ml micro-centrifuge tubes and either a Bradford Assay 
(section 3.5.4.1) or spectrophotometric analysis (section 3.5.4.2) was carried out to 
determine the concentration of purified protein. 
3.5.3. Protein incubation 
Protein was purified separately on a column with affinity for the specific tag (section 
3.5.2). Protein concentration in the eluted fractions was measured using a Bradford 
Assay and adjusted for each sample to a 1:1 mixture ratio. Combinations of protein 
were incubated together for 12 hours at either 4 °C or 37 °C, whilst shaking. 
3.5.4. Analysis of Protein Concentration 
3.5.4.1. Bradford Assay 
To calculate the concentration of protein the sample was diluted in dH2O in a 96-well-
plate. The following dilutions of 0.02, 0.05, 0.1 and 0.2 mg/ml BSA in dH2O were 
used to delineate a standard curve. Bradford reagent (BioRad) was diluted 1:4 in 
dH2O and 200 µl added to both standard and protein samples. Protein binding to the 
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dye stabilises its blue anionic form and the increase of absorbance at 595 nm is 
proportional to the quantity of bound dye and thus to the concentration of protein in 
the sample. To measure the protein concentration the plate was read at 595 nm on a 
Synergy HAT plate reader combined with KC4 Kineticalc for WindowsR software 
(both from BioTEK Instruments). The concentration was calculated in mg/ml.  
3.5.4.2. Spectrophotometric analysis using Nanodrop 
To calculate the concentration of purified protein in the elution fractions the Thermo 
Scientific NanoDropTM 1000 Spectrophotometer in combination with the Nanodrop 
1000 3.7.1 software was used. An aliquot of 1.2 µl of sample was applied and the 
absorption rate (A) at 280 nm was measured. The accurate protein concentration (c) 
in mg/ml was calculated according to equation 3.2. The extinction coefficient (ε = 
70820) was determined using Expasy (http://www.expasy.org) under specification of 
the entire amino acid sequence (Figure 4.10). 
 
3.6. Gel Electrophoresis and Western Blotting Analysis 
3.6.1. SDS-Polyacrylamide Gel Electrophoresis  
Solutions 
 1x SDS Running buffer 
Tris Base  25 mM 
Glycine  200 mM 
SDS  1 %  
 SDS Sample Buffer (Laemmli Buffer) 
Tris-HCl pH 6.8   60 mM  
Glycerol  10 %  
SDS  2 %  
-mercaptoethanol  100 mM  
Bromophenol Blue   1 %  
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Resolving Gel 12 % (ml) Stacking Gel 5 % (ml) 
3.3  
4.0  
2.5  
0.1  
0.1  
0.004 
H2O 
Acrylamide mix 30 % 
1.5 M Tris (pH 8.8) 
SDS 10 % 
Ammonium persulfate (10 %) 
TEMED 
1.4 
0.33 
0.25 
0.02 
0.02 
0.002 
H2O 
Acrylamide mix 30 % 
1.0 M Tris (pH 6.8) 
SDS 10 % 
Ammonium persulfate (10 %) 
TEMED 
Table 3.9. Solutions for a 12 % SDS-PAGE Gel (according to protocols in Molecular 
Cloning, Sambrook et al.) 
Methodology  
A 12 % SDS gel was used throughout in order to achieve optimal protein separation. 
BenchmarkTM Protein Ladder, MagicMarkTM XP Western Standard and SeeBlue™ 
Pre-Stained Standard (Invitrogen) were used as protein markers with standard 
molecular weights as a comparison to the actual protein (Figure 3.2). Samples were 
diluted with dH2O and SDS sample buffer to obtain a final protein concentration of 1 
µg/µl. The samples were boiled for 10 minutes to further denature the protein. The 
gel was inserted into the gel tank (XCell SureLock™ Mini-Cell, Invitrogen), 
submerged in 1x SDS running buffer and 10 µl aliquots of sample were loaded onto 
the gel. A 200 Volt electric current was applied for 1 hour.  
 
Figure 3.2. Invitrogen Markers used in this study. 
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3.6.2. Native Polyacrylamide Gel Electrophoresis  
Solutions  
 1x Native Running buffer 
Trizma ® base  25 mM 
Glycine  200 mM  
 Native Sample Buffer  
0.5M Tris-HCl pH 6.8   60 mM  
Glycerol  10 %  
Bromophenol Blue   1 %  
Native resolving Gel 8 % (ml) Native stacking Gel 5 % (ml) 
4.7 
2.7 
2.5  
0.1  
0.006 
H2O 
Acrylamide mix 30 % 
1.5 M Tris (pH 8.8) 
Ammonium persulfate (10 %) 
TEMED 
1.42 
0.33 
0.25 
0.02 
0.002 
H2O 
Acrylamide mix 30 % 
1.0 M Tris (pH 6.8) 
Ammonium persulfate (10 %) 
TEMED 
Table 3.10. Solutions for a 8 % native PAGE-Gel (according to protocols in Molecular 
Cloning, Sambrook et al.) 
All samples were diluted with native sample buffer to a final concentration of 10 µg/ml 
and the gel was submerged in native running buffer. The samples were loaded on to 
the gel and a native marker (NativeMark, Invitrogen) was added as a reference. 
During the 2 hours run at 100 Volts the gel tank was placed inside an ice-box to 
prevent it from overheating.  
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3.6.3. Coomassie stain 
Solutions  
 Coomassie Blue Stain  
Brilliant Blue 0.25 %  
Methanol  50 % 
dH2O  50 % 
Glacial acetic acid  10 % 
Following Gel-Electrophoresis the native or SDS gel was placed inside a box, 
submerged in coomassie stain and left on a rocker for 30 minutes. The gel was 
rinsed carefully with distilled water and heated in a microwave for 10 minutes. 
Heating was repeated until the desired resolution was achieved. The destained gel 
was dried using the DryEase® gel drying system from Invitrogen and stored between 
two sheets of cellophane. 
3.6.4. Western blotting 
Solutions  
 Transfer buffer  
Tris-HCl pH 8.0   25 mM  
Glycine   192 mM  
Methanol  2 %  
 PBST  
NaCl  140 mM  
KCl  3 mM  
Na2HPO4   10 mM  
KH2PO4  2 mM  
Tween 20  0.05 % 
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 Blocking Solution 
5 % dry non-fat milk powder in PBST 
Methodology  
After completion of either SDS or Native PAGE the stacking gel was removed and a 
nitrocellulose membrane was placed on top of the gel with filter paper and blotting 
pads around it (Figure 3.3). The whole “sandwich” was placed inside a transfer cell 
(XCell®), transfer buffer was added and a constant current of 30 Volts was applied 
for 1 hour causing the proteins to move from the gel onto the membrane. Once the 
transfer was finished the membranes were submerged in blocking solution and left 
shaking for 1 hour at room temperature. Three repeats of five minute washing steps 
in PBST were completed and the primary antibody (Table 3.11) was incubated for 1 
hour, followed by another three 5 minute washing steps in PBST. The membrane 
was exposed to the appropriate secondary antibody (Table 3.12), conjugated to the 
reporter enzyme horseradish-peroxidase. Three additional 5 minute washing steps in 
PBST followed. In the dark the chemiluminiscent agent ECL Plus™ (GE Healthcare) 
was applied to the membrane, producing luminescence in proportion to the amount 
of protein bound. The signal was detected using a sheet of photographic film and 
exposing for 15-30 minutes. The film was developed and fixed (Kodak) to obtain 
suitable resolution. 
 
Figure 3.3. Setup for a western blot transfer using XCell II™ Blot Module (Invitrogen). 
Taken from the XCell manual. 
Materials & Methods | Gel Electrophoresis and Western Blotting Analysis 
 
 
32 
 
Antibody Host Dilution Recognition site Source 
MAB5308 Mouse mAB 1/1000 Human BACE Millipore 
-MBP Mouse mAB 1/500 MBP derived of malE gene of E.coli Invitrogen 
PC478 Rabbit pAB 1/1000 aa 44-59 of human BACE Calbiochem 
9E10 Mouse mAB 1/1000 aa 408-432 human c-Myc Abcam 
-FLAG Mouse mAB 1/1000 FLAG Sigma-Aldrich 
Table 3.11. Primary antibodies used in this study. 
Antibody Host Dilution Conjugate Source 
Anti-Mouse Goat 1/10000 H&L Chain Specific Peroxidase Calbiochem 
Anti-Rabbit Donkey 1/10000 HRP-Linked Whole Antibody GE Healthcare 
Table 3.12. Secondary antibodies used in this study. HRP: Horseradish Peroxidase, H&L: 
heavy and light chain. 
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CHAPTER 4 
RESULTS 
4.1. Introduction 
Alzheimer’s disease is a neurodegenerative disorder where cause and progression 
are still not well understood. Research indicates that the disease is associated with 
the accumulation of misfolded -amyloid, a small peptide, 39–43 amino acids in 
length, which originates from a larger precursor protein (APP). Inhibiting the activity 
of the -amyloid converting enzyme 1 (BACE1) decreases the production of -
amyloid. Membrane bound reticulon (RTN) family proteins interact with BACE1 and 
negatively modulate BACE1 activity through preventing access of BACE1 to its 
cellular APP substrate (He et al., 2004). This study focused on RTN3, which is largely 
expressed in neurons and therefore a potential candidate for inhibiting BACE1. The 
general aim of this study was to reconstitute binding between BACE1 and RTN3. 
4.2. Expression of RTN3 in cell cultures 
The first approach to investigate the interaction between RTN3 and BACE1 was to 
replicate the results observed by He et al. (2004). In these experiments a SH-SY5Y 
derived cell line (5Y°) was used, which stably expresses C-terminally MYC-tagged 
BACE1 (Dr Ruth Rose, Kings College, London). 
4.2.1. Lysis of BACE1-MYC cells 
In a preliminary experiment cell lysis conditions were evaluated. Since the detergents 
were not disclosed in the original paper describing the interaction (He et al., 2004), 
different types and concentrations of commonly used lysis buffers were assessed in 
the efficacy to extract membrane-bound BACE1-MYC protein. A solution of 0.1 % 
Triton X-100 buffer proved to be the most efficient in the lysis of BACE1-MYC over-
Results | Expression of RTN3 in cell cultures 
 
 
34 
 
producing 5Y° cells and allowed a good resolution of BACE1-MYC by western blot 
(Figure 4.1).  
 
Figure 4.1. Different concentrations of lysis buffer were assessed. Cells were lysed with 
0.1% NP-40, 0.5% NP-40 and 0.1% Triton X-100. Triton X-100 induced the generation of 
smaller micelles and therefore liberated clearly more BACE1. Antibody: MAB5308 
This way the efficiency of 5Y° cells in over-producing BACE1-MYC was verified and 
successful liberation of the integral membrane protein by the employed detergent 
was confirmed. 
4.2.2. Transfection of BACE1-MYC cells with pFLAG-RTN3 
BACE1-MYC-5Y° cells were transiently transfected with full length FLAG-tagged 
RTN3. The pFLAG-RTN3-CMV-6c template was received from Dr Mitsuo Tagaya, 
Department of Pharmacy & Life Science at Tokyo University. Cells were allowed to 
grow for 3 days at 37 °C with 95 % air and 5 % CO2. For all further experiments a 
preparation of crude cell lysates was used. Cell lysis was carried out in 0.1 % Triton 
X-100 buffer and a Bradford assay was done to calculate and adjust the 
concentration of protein (1 µg/µl). The lysates were directly applied to SDS-PAGE. 
Results were observed by Western Blot, using Anti-FLAG and Anti-BACE (MAB5308) 
antibodies. BACE1-MYC showed a good resolution on the gel (Figure 4.2). However, 
no FLAG-RTN3 was observed in transfected cells (data not shown). 
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Figure 4.2. Western blot for BACE1-MYC in 5Y° cells. BACE1-MYC is represented by the 
prominent band around 70kDa. Transfection was performed in triplicate. Control denotes 5Y° 
cells without transfection. Antibody: MAB5308.  
Attempts to optimise transfection conditions were implemented but to no avail. For 
this reason an alternative method was employed to investigate BACE1 and RTN3 
interaction.  
4.3. Recombinant production of RTN3 and BACE1 
4.3.1. General approach 
An alternative approach to investigate the interaction between RTN3 and BACE1 
involved using recombinantly produced RTN3 and BACE1. The domain encoding the 
proposed binding site of RTN3 (section 4.3.2) was cloned into the expression vector 
pMal-c2x, which is designed to generate a MBP fusion protein. The malE gene on 
this vector is deleted for the signal sequence, leaving the produced fusion protein to 
remain in the cytoplasm. Cells therefore need to be lysed (section 3.5.1.2) and then 
purified (section 3.5.2). The introduction of a MBP tag facilitated one-step affinity 
protein purification and allowed quick and efficient isolation of RTN3. Figure 4.3 
illustrates a more detailed schematic of the process. 
Advantages and limitations of a recombinant approach will be discussed in more 
detail in chapter 5. 
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Figure 4.3. MBP fusion protein. The cloned gene is inserted into a restriction site of the 
vector polylinker, in the same translational reading frame as the malE gene, which encodes 
maltose-binding protein (MBP). This results in the expression of an MBP-fusion protein. The 
technique uses the strong Ptac promoter and the translation initiation signals of MBP to 
express large amounts of the fusion protein. The fusion protein is purified using an amylose 
column. (pMAL™ Protein Fusion and Purification System, NEB) 
4.3.2. Identification of the RTN3 Homology Domain 
In order to reconstitute interaction between RTN3 and BACE1 it was decided to use 
a RTN3 variant containing only the region that was proposed to mediate binding. 
RTN proteins are characterised as a group of membrane bound proteins that share a 
highly conserved C-terminal Reticulon Homology Domain. The interaction of BACE1 
with all four RTN members implies that this domain may mediate binding of RTNs to 
BACE1 (He et al., 2004). It was previously shown that a completely conserved QID 
amino acid triplet within the C-terminal tail of RTNs is critical for the interaction (He et 
al., 2006). For the following studies a truncated RTN3, termed RTN3 Homology 
Domain (RTN3 HD), was designed, consisting merely of the last C-terminal 40 amino 
acids including the anticipated binding site (QID) but lacking predicted loop and 
transmembrane regions. 
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Figure 4.4. BACE1-RTN3 interaction domains. The proposed binding sites are underlined 
in red. In this study both BACE1 and RTN3 were truncated to the specified amino acid 
sequence. (C. Dingwall, King’s College London) 
4.3.3. Cloning of RTN3 HD  
Primers were designed to replicate the C-terminal homology domain of RTN3 which 
will be referred to as RTN3 HD from here on. Additionally the restriction sites for 
BamHI and HindIII were incorporated into the sequence to allow the gene to be 
inserted into pMal-c2x. The amplification of RTN3 HD is shown on the diagram below 
(Figure 4.5). 
 
Figure 4.5. Amplification of the Homology Domain. The primers BamHI and HindIII were 
incorporated into the sequence. 
Polymerase Chain Reaction (PCR) was used to amplify the selected DNA sequence. 
DNA fragments were analysed by agarose gel electrophoresis (Figure 4.6), 
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extracted, digested with the designated restriction enzymes and ligated into the pMal-
c2x expression vector. JM109 cells were transformed with the ligation product and 
screened by colony PCR (data not shown) to identify colonies that carried the insert. 
Four colonies containing the insert were picked and a miniprep was prepared. An 
analytical restriction digest confirmed the presence of the insert (Figure 4.7) and 
isolated DNA was sent in for sequencing (Figure 4.8). The result determined the 
nucleotides of the template DNA to be in alignment with the predicted sequence 
(Figure 4.9).  
 
Figure 4.6. PCR 
RTN3 HD DNA was amplified in 
triplicate and analysed by agarose 
gel electrophoresis. Bands appearing 
at appropriate size (139 bp) were 
excised, extracted, digested and 
ligated into the vector pMal-c2x. The 
ligation product was introduced into 
JM109 competent cells. Commercial 
100bp marker used: see page 20. 
 
Figure 4.7. Restriction digest 
An analytical digest with 2 different 
restriction enzymes was performed 
to check if DNA strands were ligated 
correctly. Resulting constructs were 
compared to the empty vector pMal-
c2x (5). The low MW bands of 
construct 3 & 4 show at 1309 bp, 
considerably higher than the vector’s 
band (1201 bp) which suggests they 
carry the insert. Colony 20 and 30 
were sent in for sequencing at GATC 
Biotech (Konstanz, Germany). 
A   B   C   
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Figure 4.8. Sequencing results from GATC (Konstanz, Germany). Colony 30 was selected 
as it had the correct sequence alignment. 
RTN3 HD was successfully cloned into the vector pMal-c2x. 
 
Figure 4.9. MBP-RTN3 HD sequence alignment. Red marks aligned base pair; blue, 
different base pair; dots indicate deletions. Alignment was verified using MultAlin 
(http://bioinfo.genotoul.fr/multalin/ multalin.html). 
 
Figure 4.10. Translated amino acid sequence of sequenced pCW01 expression vector. 
The frames mark maltose binding protein, linker protein and RTN3 HD. Molecular weight 
according to Expasy (http://www.expasy.org): 47574.8 Da. 
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4.3.4. Protein Production 
Protein production was assessed by a small scale trial (20 ml). Competent BL21-
Codonplus(DE3)-RIL cells were transformed with the pMal-c2x-RTN3 HD expression 
vector, containing the verified sequence (pCW01), and colonies were selected on 
ampicillin and chloramphenicol. Cells were grown at 37 °C until an A600 of 0.6-0.8 
was obtained. Protein production was induced by the addition of IPTG. The cells 
were either maintained at 37 °C or transferred to 17 °C and were kept shaking. After 
2 hours, one flask grown at 37 °C and one at 17 °C were harvested by centrifugation. 
All remaining cultures were left to grow overnight. The cells were pelleted and 
resuspended in 50 mM Tris pH7.4, 100 mM NaCl. Cells were lysed by sonication and 
pelleted by centrifugation. All samples were run on a Western Blot to confirm the 
presence of MBP-RTN3 HD (Figure 4.11).  
 
Figure 4.11. Induction trial. Protein production was induced with IPTG, cells were grown at 
37°C or 17°C, samples were taken after 2 hours and 12 hours (o/n). P: post lysis pellet 
resuspended in column buffer, Sn: post lysis supernatant. Marker: SeeBlue®. AB: -MBP. 
MBP-RTN3 HD bands appeared at the expected size of 48 kDa. Overnight protein 
production at 17 °C generated the greatest yield (Figure 4.11); therefore all further 
studies were carried out under these conditions. It was also observed that following 
cell lysis a significant concentration of protein still remained in the pellet. 
  
Nr Temp °C Induction Vol 
1 37 o/n 20 
2 37 2h 20 
3 17 2h 20 
4 17 o/n 20 
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4.3.5. Protein Purification 
Purification of MBP-RTN3 HD was accomplished using a one-step affinity purification 
column that allowed fast, efficient and non-denaturing protein extraction directly from 
microbial cultures. The plasmid carrying MBP-RTN3 HD was introduced into the 
expression strain and recombinant protein was produced in a large scale induction 
culture (0.5 litres), growing at 17 °C overnight as described above (section 4.3.4). 
The cells were lysed by sonication, pelleted by centrifugation and the supernatant, 
containing the soluble protein, was applied to an amylose column with high affinity for 
the MBP fusion protein. The acquired fractions were stored and analysed by SDS-
PAGE to evaluate protein purification and expression levels. Results are shown in 
Figure 4.12. 
        
Figure 4.12. SDS-PAGE analysis of affinity purification of MBP-RTN3 HD. See table 4.1 
for sample descriptions. Elution fractions are marked red, marker in italics. 12% SDS gel. 
The elution fraction containing the purified MBP-tagged RTN3 HD protein showed a 
sharp band at approximately 48 kDa which is consistent with the expected size. A 
weaker band was also detected at 38 kDa, possibly being evidence of protein 
fragmentation as it was consistently visible in 3 purification repeats under the stated 
conditions (data not shown).  
Regarding these outcomes the presented method was considered an efficient and 
reproducible way to produce recombinant RTN3 HD at a substantial yield. 
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4.3.6. Potential dimerisation of MBP-RTN3 HD 
In a separate experiment purified elution fractions of MBP-RTN3 HD were run on 
native PAGE to study the generation of complexes and oligomers. These gels 
indicated the presence of an additional band at approximately 90 kDa (Figure 4.13), 
possibly representing a dimer. MBP-RTN3 HD dimers were calculated to appear at 
about 95 kDa. Bands corresponding to that size were visible throughout on all native 
gels (section 4.3.9).  
These findings are in accordance with observations made by He et al., 2006, who 
identified RTN3 homo- and heterodimerisation. Additional contaminating bands were 
detected at approximately 25 and 30 kDa. Surprisingly, no band was observed at 48 
kDa, matching the calculated size of the original MBP-RTN3 HD monomer. As it 
appears these monomers instantly aggregate to form larger complexes that can only 
be separated by strong denaturing conditions.  
 
Figure 4.13. Native-PAGE analysis of individual purification of MBP-RTN3 HD. Run with 
NativeMark. 8% native gel. 
As it was not entirely clear how these complexes evolve, several investigative trials 
were conducted to characterise the interaction. The result of this analysis can be 
found in section 4.3.8. 
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4.3.7. Dual-Purification of MBP-RTN3 HD and GST-BACE1 
Based on the common principles of Immunoprecipitation and Tandem Affinity 
Purification (Puig et al., 2001) a new method was developed to combine both protein 
purification and binding studies of RTN3 HD and BACE1. Immunoprecipitation uses 
protein A or G beads coated with an antibody that is specific for a known motif to 
isolate it from a crude lysate. In contrast, Tandem Affinity Purification involves the 
creation of a fusion protein with a TAP-tag consisting of Protein A that binds tightly to 
IgG and calmodulin binding peptide. The protein of interest is then retrieved with two 
affinity columns binding to each moiety. 
This study adopted the technique of introducing a specific tag to retrieve the protein 
on an affinity column, in this case MBP-RTN3 HD. The second protein and potential 
binding-partner, GST-BACE1 (vector designed by Dr B Angelleti), carried a different 
tag to prevent artefactual binding. To simplify matters both proteins were applied to 
the same column and elution fractions were screened for both proteins, which would 
indicate successful protein-protein interaction. 
Gel sample Description 
Cell pellet Post lysis and centrifugation cell pellet resuspended in column 
buffer. 
Post lysis s/n Post lysis and centrifugation supernatant. 
Column f/t Lysis supernatant column flow through. 
Column wash Post binding column washed with 50 ml of column buffer. 
Elution Most concentrated fraction eluted from the column. 
Dual eluate Most concentrated elution fraction after dual purification. 
MBP-RTN3 MBP-tagged homology domain of RTN3. 
Table 4.1. Caption of all samples used for SDS-PAGE and Western Blot analysis of the dual 
purification. 
The crude cell extracts of freshly produced MBP-tagged RTN3 HD were applied to an 
amylose column allowing the fusion protein to bind directly to the polysaccharide 
resin whilst all other bacterial proteins were removed by washing under gravity flow. 
The first protein, MBP-RTN3 HD, was now held in solid phase by MBP and the 
second lysate, containing GST-BACE1 was applied in a liquid phase. The fusion 
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proteins were given time for their C-terminal partners to interact, then the column was 
washed again. The protein-complex was eluted from the amylose resin with maltose. 
All fractions were collected and run on SDS- and native PAGE. The results were 
observed by coomassie staining (Figures 4.14, 4.16) and Western Blot (Figure 4.15). 
 
Figure 4.14. SDS-PAGE analysis of dual purification of MBP-RTN3 HD and GST-
BACE1. Table 4.1 for sample descriptions. Elution fractions are marked red, marker in italics. 
 
Figure 4.15. Western blot of dual purification. MBP-RTN3 HD was clearly detected by the 
-MBP antibody in both elution fractions at 48kDa. GST-BACE1 was not observed in the 
dual eluate despite being visible in the flow-through and washing fractions.  
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Figure 4.16. Native PAGE analysis of dual purification. Run with NativeMark. See table 
4.1 for sample descriptions. 8% native gel. 
In the elution fraction there is no distinct band detectable at 30 kDa on the denaturing 
SDS gel (Figure 4.14) although GST-BACE1 is clearly visible in the post-lysis 
supernatant and the column flow-through. This result was once more confirmed by 
Western Blot using specific antibodies against BACE1 and MBP (Figure 4.15). It is 
therefore evident that MBP-RTN3 HD and GST-BACE1 were not eluted together as a 
consequence of interaction. The product is contaminated with several other bands 
including the previously observed fragment at 38 kDa (Figure 4.12).  
A non-denaturing native gel (Figure 4.16) showed a high molecular weight band at 
approximately 90 kDa that could indicate successful protein-protein interaction. 
However, previous studies have confirmed the presence of a potential MBP-RTN3 
HD dimer at that particular size (Figure 4.13). Along with the inconclusive result of the 
SDS-PAGE and Western Blot this does not confirm binding of RTN3 to BACE1. 
Consequently an alternative and more direct methodology was employed. 
4.3.8. Individual purification and incubation 
To enhance the possibility of both proteins interacting with each other, MBP-RTN3 
HD, GST-BACE1 and a negative control of GST were purified individually on an 
affinity column specific for the fusion protein (Figure 4.17). All eluted fractions 
containing purified protein were incubated together in a series of experiments under 
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various conditions. Two different combinations of protein were maintained for 12 
hours at either 37 °C or 4 °C and then run on SDS (data not shown) and native 
PAGE (Figure 4.18). 
 
Figure 4.17. SDS-PAGE analysis of individual purifications for MBP-RTN3 HD, GST-
BACE1 and GST. Run with BenchMark. See table 4.1 for sample descriptions. 
 
Figure 4.18. Native-PAGE analysis of individual purifications for MBP-RTN3 HD, GST-
BACE1 and GST. Run with NativeMark. Purified proteins from the elution fractions (red) 
were incubated (blue) overnight at 37°C with gentle agitation at a 1:1 ratio. 8% native gel. 
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All SDS gels run with purified samples show sufficient levels of protein production for 
the incubation studies (Figure 4.17). Hence an adequate concentration of protein was 
provided for all further binding assays (10 µg/ 10 µl). For the investigation of potential 
protein-protein interaction a non-denaturing native gel was used. If native PAGE is 
carried out near neutral pH to avoid acid or alkaline denaturation, it can be used to 
study conformation, self-association or aggregation, and the binding of other proteins 
or compounds. 
Elution fractions were incubated in two combinations (Figure 4.18) and run on the 
native gel. Higher molecular weight bands at approximately 90 kDa were identified in 
the incubation samples corresponding to those observed in the elution fractions. As 
discussed in section 4.3.6 this could be evidence for oligomerisation of MBP-RTN3 
HD whilst it seems very unlikely that protein binding occurred during the incubation 
period.  
4.3.9. Analysis of the interaction 
To further probe the interaction, all proteins were purified separately under a variety 
of conditions, incubated and run on a native gel to be confident of complex formation. 
Samples were incubated for either one hour (data not shown) or overnight, at 4 °C 
and 37 °C. 
High salt conditions 
 
Figure 4.19. Native-PAGE of individual purifications of MBP-RTN3 HD, GST-BACE1 and 
GST with addition of 500 mM NaCl to all buffers. Overnight incubation at 4 °C & 37 °C (blue). 
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In general, the addition of salt disrupts protein-protein interactions on the basis of 
charge. Increasing the salt concentration reduces the strength of ionic binding by 
providing competing ions for the charged residues of a protein. In this study the 
concentration of NaCl in all purification buffers was increased to 500 mM in order to 
observe alterations in protein structures caused by ionic charges. High salt conditions 
severely diminished the concentration of purified protein in the elution fractions. In 
particular GST-BACE1 was affected with protein levels being below the threshold of 
detection. This observation and the general loss of intensity in most bands are largely 
due to precipitation. High-salt conditions are known to promote the interaction of 
surface hydrophobic regions on proteins, inducing the formation of aggregates that 
separate from the water (Marshak, 1996). However, the grade of multimerisation 
observed by native PAGE (Figure 4.19) resembled those seen under the standard 
purification conditions (Figure 4.18). 
Low salt conditions 
 
Figure 4.20. Native-PAGE of individual purifications of MBP-RTN3 HD, GST-BACE1 and 
GST with addition of 100 mM NaCl to all buffers. Overnight incubation at 4 °C & 37 °C (blue). 
Low salt conditions or a reduced number of free ions in solution are expected to 
enhance the strength of ionic binding among the charged groups on the surface of a 
protein. In this study, a significant increase in multimerisation in MBP-RTN3 HD and 
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GST-BACE1 samples was induced. In contrast to high salt purification conditions, a 
GST multimer appeared also, visible in the GST elution fraction as well as in GST-
BACE1 samples. 
MBP-RTN3 HD showed slightly less multimerisation when incubated overnight at 
37°C suggesting temperature-dependent degradation of higher molecular weight 
complexes (Figure 4.20).  
There was no evidence for binding between incubated samples of GST-BACE1 and 
MBP-RTN3 HD induced by low salt purification conditions. Individual proteins tended 
to interact with themselves and oligomerise more readily during purification. 
However, this did not have any effect on heterogenous interaction during incubation. 
Strong reducing conditions (DTT) 
 
Figure 4.21. Native-PAGE of individual purifications of MBP-RTN3 HD, GST-BACE1 and 
GST with addition of 5 mM DTT to all buffers. Overnight incubation at 37 °C (blue). 
Dithiothreitol (DTT) is a strong reducing agent, commonly used to reduce disulfide 
bonds of proteins via two sequential thiol-disulfide exchange reactions. Thus it is 
capable of disrupting protein folding and aggregation by preventing intramolecular 
and intermolecular disulfide bonds from forming between cysteine residues of 
proteins.  
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Compared to standard conditions (Figure 4.18) there were no differences detectable 
in MBP-RTN3 HD multimerisation (MBP-RTN3 Elution) when purified in the presence 
of DTT (Figure 4.21). As MBP-RTN3 HD does not contain any cysteine residues and 
methionine cannot form disulfide bonds, the complex may be stabilised by non-
covalent hydrogen bonding or ionic interaction and these bonds could be solvent-
inaccessible. Stronger denaturing conditions, such as addition of SDS in combination 
with -mercaptoethanol and heat, caused these quaternary structures to disintegrate 
(Figure 4.14) and liberated MBP-RTN3 HD (48 kDa) and two smaller fragments. In 
the incubating samples MBP-RTN3 HD did not seem to interact with either GST-
BACE1 or GST. 
Multimerisation was also detected in purified GST-BACE1 samples (GST-BACE1 
Elution), correlating to the observation made under standard conditions. Interestingly, 
GST alone showed no complex formation, suggesting that fused BACE1 could bury 
disulfide bonds of GST-BACE1 multimers which therefore cannot be reduced by 
DTT.  
Overall, when employing high salt or strong reducing purification conditions no time 
or temperature dependence was observed in the behaviour of protein. Low salt 
conditions showed a temperature-dependent degradation of MBP-RTN3 HD 
multimers when incubated overnight at 37 °C. 
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CHAPTER 5 
DISCUSSION 
5.1. RTN3 in cell culture 
In recent years Co-Immunoprecipitation (Co-IP) has become a common method to 
demonstrate the interaction between proteins, including transmembrane aspartic 
proteases such as BACE1 (He et al., 2004; Murayama et al., 2006). These protocols 
have employed various detergents to solubilise the cell membrane and extract the 
protein without thorough consideration of the mechanism of membrane disruption by 
detergents and the possible artefacts that could arise as a consequence of misuse.  
When a low concentration of detergent is added to a membrane, the detergent 
molecules, comprising a hydrophobic tail and a hydrophilic head group, intercalate 
into the bilayer. The behaviour of the detergent is dependent on character and 
stereochemistry of the head group and tail (Garavito and Ferguson-Miller, 2001). The 
concentration of the detergent also plays an essential role. At a certain threshold, 
called the critical micelle concentration (CMC), detergent monomers self-associate 
and form micelles. Once the concentration surpasses the CMC, the detergent 
becomes able to solubilise hydrophobic and amphipathic molecules, such as lipids 
(Rosen et al., 1978) and even integral membrane proteins to create water-soluble 
protein-detergent complexes (Garavito and Ferguson-Miller, 2001). These mixed 
micelles vary considerably in structure and size depending on the type and 
concentration of the detergent used. The size of the micelle dictates the size of the 
membrane fragment and the proteins associated with it. At this stage it is crucial to 
chose carefully and balance possible effects of the detergent on the isolated protein. 
Numerous studies have used Triton X-100 as the benchmark detergent for similar 
studies, though it has been shown to give poor reproducibility between different 
experiments with the same starting material (Lingwood and Simons, 2007). 
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Variations in the size of the micelles may alter the yield or even cause a mixing of 
proteins that originally were located on different membrane areas (Madore et al., 
1999). All this will have an impact on the Immunoprecipitation as well. It is indeed 
conceivable that two proteins localised in the same membrane region will Co-IP 
together although they do not necessarily bind directly to each other. Therefore, it is 
important to ascertain that protein-protein binding is genuine and not a result of 
artefacts made by the detergent.  
To investigate whether BACE1 and RTN3 co-IPed together artefactually, it was 
decided to reconstitute the original approach published by He et al. (2004). In the 
published paper a HEK-293–derived stable cell line was used that expressed BACE1 
tagged with hemagglutinin A (HA) at its C-terminus. To examine reticulon binding to 
BACE1, lysates from cells transfected with MYC-tagged RTN family members were 
prepared and a monoclonal antibody to HA was used for co-Immunoprecipitation, 
followed by western bot analysis with an antibody to the MYC-epitope of reticulon. 
Since the detergents originally employed were not stated in the paper, conventional 
detergents such as NP-40 and Triton X-100 were selected for this study, which are 
most commonly used for solubilising membrane proteins. NP-40 has already been 
tested for reproducibility with RTN3 and BACE1 by Murayama et al. (2006). In order 
to verify the functional efficiency of BACE1-MYC over-expressing 5Y°s, all cells were 
lysed in a small scale trial using various concentrations of Triton X-100 and NP-40. 
Results were observed by Western Blot and confirmed that the applied detergent 
successfully liberated integral membrane proteins. The highest yield of protein was 
obtained using a concentration of 0.1 % Triton X-100. To test the interaction BACE-
MYC 5Y°s were transfected with FLAG-RTN3 and the crude cell lysates examined 
using SDS-PAGE and Western Blot. Although BACE1-MYC was clearly visible on the 
gel at the calculated molecular weight, FLAG-RTN3 could not be detected, 
suggesting that it was not expressed properly. There are a number of reasons for low 
transfection efficiency including poor DNA quality, DNA degradation, time-dependent 
changes in the cell line or insufficient cell density due to excessive cell death. 
Attempts were made to optimise transfection conditions by varying Lipofectamine 
concentrations and using different antibodies(Table 3.12) but to no avail. 
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In conclusion, transfecting a BACE1-MYC stable cell line with FLAG-RTN3 did not 
show the anticipated protein-protein interaction. Consequently, the results obtained 
by He et al. (2004) could not be reproduced. Furthermore, it remained questionable if 
the detergents employed in their previous studies then promoted genuine binding 
between RTN3 and BACE1. Therefore an alternative approach was considered to 
reconstitute binding without the limiting effects of detergents. 
5.2. Recombinant production of RTN3 
In a novel approach it was decided to focus primarily on the predicted binding sites of 
both RTN3 and BACE1. The protein-protein interaction has been proposed to be 
mediated by a sequence in the RTN3 homology domain (RTN3 HD) and the C-
terminal tail of BACE1, respectively. In this study the last 40 C-terminal amino acids 
of RTN3 were cloned, representing the C-terminal tail of the HD without loop or 
transmembrane regions (RTN3 HD). BACE1 was truncated to the C-terminal 24 
amino acids. The main reason for this was to eliminate interference by different 
protein processing, such as folding or integration into the plasma membrane. If this 
interaction is stable it should be detectable using the minimal amino acid sequence of 
the predicted binding sites.  
To this end, the gene encoding the RTN3 HD was successfully cloned into the 
expression vector pMal-c2x. Sequencing revealed that the RTN3 HD sequence in the 
expression vector aligned with the template DNA and the translated sequence was in 
frame with the maltose binding protein (MBP). 
For binding studies a large quantity of purified protein is required. This requires that 
most recombinant protein is recovered in the liquid phase after cell lysis. MBP was 
used as a tag to artificially enhance solubility of the RTN3 HD fusion protein. E. coli 
MBP has been proven to be a more effective solubility partner than GST and 
thioredoxin proteins in a comparison of solubility enhancing properties (Soerensen 
and Mortensen, 2005). Nevertheless, the solubility of the fusion protein also depends 
on the properties of the recombinant partner and may therefore vary. Another reason 
to choose MBP-tagging was its high affinity for column-bound amylose which allows 
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one-step purification of the protein with a system readily available in the laboratory 
(see Protein Purification).  
Once successful cloning of the gene was confirmed, competent BL21-
Codonplus(DE3)-RIL cells were transformed with the expression vector pMal-c2x and 
induced to produce recombinant protein. 
5.3. Protein purification 
The MBP-RTN3 HD fusion protein was purified using an Amylose column with high 
affinity for MBP. The presented method proved to be an efficient and reproducible 
way to obtain an adequate quantity of the 48 kDa fusion protein, MBP-RTN3 HD, 
which was visualised by SDS-PAGE. 
Purity of the elution fractions, however, was not fully achieved. A recurring 
observation by SDS-PAGE was the contamination of the elution fraction with two 
proteins with molecular weights of 45 and 38 kDa. These contaminants were 
detectable by immunoblotting with Anti-MBP and coomassie staining, suggesting 
they represent degraded products of MBP-RTN3 HD generated by strong denaturing 
conditions. In contrast, non-denaturing native gels showed contaminants at 25 and 
30 kDa. Here, the majority of protein was represented by a higher molecular weight 
band at 90 kDa, which will be discussed below. 
For future studies, additional methodologies should be considered to optimise 
purification and separate RTN3 HD from contaminants. Fast protein liquid 
chromatography (FPLC) is a method commonly used to isolate proteins in complex 
mixtures. This term is applied to several chromatography techniques. Depending on 
the preferred column it can separate macromolecules based on size (size exclusion), 
charge distribution (ion exchange), hydrophobicity, reverse-phase or biorecognition 
(affinity chromatography). Many of these techniques are identical to those carried out 
under high performance liquid chromatography (HPLC), however, the use of FPLC is 
typical for preparing large scale batches of a purified product. Each column contains 
small particles or gel beads known as the stationary phase. The sample is introduced 
into the injector and carried into the column by the liquid mobile phase. Once it 
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resides in the column, the mixture of proteins gets fractionated due to different 
components adhering to or diffusing into the gel.  
In this study, size exclusion chromatography (SEC) would be a valuable method of 
separation. SEC is a gel filtration chromatography method, where proteins and 
polymers are fractionated based on their size and hydrodynamic volume. The protein 
is dissolved in an aqueous solvent and applied to a column packed with a matrix of 
porous polymer beads. Molecules smaller than the pore size can enter the particles 
and therefore have a longer transit time than larger molecules that will interact less 
with the stationary phase and thus elute faster. This method has further advantages 
in that it allows the preservation of biological activity since samples are applied under 
native conditions, leaving tertiary and quaternary structures intact. SEC measures 
the hydrodynamic volume or more specifically how much space a polymer molecule 
takes up in solution. Thus, it is also possible to distinguish folded and unfolded 
versions of the same protein. A 10 % difference in molecular mass is necessary to 
provide a good resolution. The technique can be combined with others that separate 
molecules by different characteristics, such as acidity, basicity, charge or affinity. 
Relevant bands were at 48 kDa (SDS-PAGE) and 90 kDa (native) with contaminants 
being considerably smaller and below 10 % difference. Therefore, affinity purification 
coupled with SEC would be effective in improving the isolation of MBP-RTN3 HD. 
Considering the overall yield of MBP-RTN3 HD a sufficient quantity of protein could 
be isolated with the specified techniques. However, during the procedure the yield 
varied substantially. Despite the use of the highly hydrophilic MBP-tag, the protein 
was not entirely soluble and, following lysis, substantial amounts were still observed 
in the pellet. Over-expression of cloned genes in recombinant bacteria often induces 
the aggregation of protease-resistent misfolded protein to form so-called bacterial 
inclusion bodies (Carrio and Villaverde, 2002). This remains to be a major obstacle 
for protein production and in vitro recovery of functional protein often relies on 
complex re-folding procedures. The simultaneous co-expression of chaperone-
encoding genes has also provided good results in a variety of studies with 
recombinant protein (Caspers et al., 1994; Nishihara et al., 1998, 2000). In particular 
the GroE proteins (Richardson et al., 1998; Bukau et al., 1998) have been shown to 
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accelerate the folding of MBP (Sparrer et al., 1997), consequently influencing 
solubility. The ability of MBP to promote the solubility of fusion partners can also be 
improved by addition of supplemental tags. Different configurations for MBP fusion 
proteins have been suggested for high-throughput protein expression and 
purification. According to Routzahn et al., 2002, the most promising candidate 
appeared to be a fusion protein with a biotin acceptor peptide (BAP) on the N-
terminus of MBP and/or a hexahistidine tag (His-tag) on the C-terminus of the 
passenger protein. However, due to the metal binding capacity of BACE1 (Angeletti 
et al., 2005) a His-tag for metal affinity chromatography was not suitable in this study.  
5.4. RTN3 HD oligomerisation 
Following purification, a prominent band of approximately 90 kDa was detected on all 
native gels. Surprisingly, native gels did not show the anticipated 48 kDa MBP-RTN3 
HD monomer. It was concluded that the monomers instantly multimerised to form 
larger complexes. In accordance, dimers were calculated to migrate at 96 kDa. 
The presence of RTN3 HD dimers is consistent with the observations published by 
He et al. (2006), where it was reported that RTN homo-dimerisation naturally occurs 
within cells. According to their findings, the reticulon homology domain appears to 
mediate this dimerisation, though the precise residues were not identified. In the 
experiments described here, the majority of RTN3 was present as a dimer under non-
denaturing conditions.  
In order to analyse how these multimers evolve, all proteins were prepared 
separately in strong reducing (DTT), high-salt or low-salt conditions. The addition of 
DTT did not disrupt MBP-RTN3 HD complexes, which confirms that dimerisation is 
not due to disulfide bonding. Thus the tertiary structure of MBP-RTN3 HD is 
dependent on non-covalent interactions, such as hydrogen or ionic bonding. The 
concentration of salt in the buffer was increased to characterise any ionic bonding. 
Although it was supposed to have a disrupting effect on ionic bonds, it did not alter 
the appearance of MBP-RTN3 HD dimers. Interestingly, low-salt conditions induced a 
significant increase in multimerisation at a higher molecular weight level. This 
dependency of multimerisation on a low level of ions provided in the solvent 
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environment suggests a distinct involvement of ionic bonds in the generation of 
RTN3 oligomers. Heat can be used to disrupt hydrogen bonds and non-polar 
hydrophobic interactions due to an increase in kinetic energy. SDS applies negative 
charge to amino acids and disrupts most non-disulfide-linked tertiary structures. A 
combination of SDS, heat and -mercaptoethanol liberated the 48 kDa MBP-RTN3 
HD monomer. However, these denaturing conditions were not employed to 
investigate binding. 
5.5. Binding studies 
Having successfully produced and purified MBP-RTN3 HD, methodologies were set 
up to investigate the proposed interaction between MBP-RTN3 HD and GST-BACE1. 
The first approach involved dual-purification of both proteins, a technique that 
combined purification and binding assay. The bacterial lysates of MBP-RTN3 HD and 
GST-BACE1 were sequentially applied to the same amylose column. Elution 
fractions were collected and observed by SDS-PAGE. Purified MBP-RTN3 HD was 
clearly visible at 48 kDa. However, the 30 kDa GST-BACE1 fusion protein could not 
be detected, despite being observed in the supernatant applied to the column. This 
demonstrates that protein-protein interaction did not take place on the affinity column. 
Accordingly, large quantities of GST-BACE1 were detected in the column flow 
through after being washed off the column. 
An alternative approach employed the individual purification of MBP-RTN3 HD, GST-
BACE1 and GST. The purified proteins were incubated together, in an equal ratio, to 
allow the binding-sites to interact. The purifications were varied by using strong 
reducing conditions, high salt or low salt concentrations. Purified fractions were 
combined under a variety of conditions, including different temperatures (37 °C and 
17 °C) and time frames (1 hour, 12 hours). All samples were observed by SDS-
PAGE and native gel to allow detection of the potential RTN3-BACE1 complex at a 
higher molecular weight. However, no additional bands were observed at the 
anticipated size (~78 kDa) and bands representing MBP-RTN3 HD, GST-BACE1 and 
GST were clearly separated from each other. Neither time nor temperature facilitated 
complex formation. Similarly, varying reducing conditions or salt concentrations did 
not seem to promote binding and the multimerisation detected in the purified elution 
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fractions remained precisely unchanged. As an exception, MBP-RTN3 HD purified 
using low-salt and incubated at 37 °C overnight, showed slightly less multimerisation 
compared to samples at 4 °C. This suggests a temperature-dependent dissociation 
of higher molecular weight multimers. In general, multimerisation was enhanced 
among all incubated protein purified at low-salt conditions, confirming the effect of 
salt on ionic bonding. However, it is doubtful that there is a connection between the 
low-salt induced generation and degradation of MBP-RTN3 HD multimers and the 
binding of RTN3 HD to BACE1. 
In summary it is evident that, under these conditions, no stable protein-protein 
binding occurred between BACE1 and RTN3.  
5.6. Possible reasons why GST-BACE1 and MBP-RTN3 HD failed 
to interact 
Major advantages of prokaryotic recombinant protein expression systems include the 
availability of simple expression vectors and the ease at which they can be grown 
rapidly at high density on inexpensive substrates. Recombinant gene products will 
accumulate in E. coli at high levels in a full-length and biologically active form. Then 
again, over-production of heterologous proteins is sometimes accompanied by their 
misfolding and segregation into insoluble aggregates. A considerable quantity of 
protein may still be recovered from the post-lysis pellet. As protein is not secreted 
into the media but stays inside the cell, specific lysis techniques and purification 
systems are required to collect and separate functional protein from bacterial cell 
residues. In this study successful isolation was achieved by tagging the desired 
protein.  
An important aspect in the use of recombinant systems is the absence of 
modification machinery in bacteria. Depending on the particular protein it may not be 
functional without specific post-translational modifications, potentially posing a dead-
end to enzymatic studies. These modifications commonly include glycosylation or the 
addition of functional groups, support folding and are involved in structural changes 
of the protein. Above all they are involved in the formation of structural 
characteristics, affecting for example the generation of disulfide bonds. Therefore, it 
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is not advisable to use a recombinant expression system for proteins containing 
multiple disulfide bonds. This did not pose a problem since the truncated C-terminal 
tail of the RTN3 homology domain does not include any cysteine residues. 
Nevertheless, little is known about posttranslational modifications necessary for the 
functionality of RTN3 or the interaction with BACE1. In order to avoid problems of this 
kind a different expression vector could be used and the host cell changed. Insect or 
yeast cells rely on eukaryotic processing and can provide many of the key 
modifications as well as suitable secretory pathways to prevent the generation of 
inclusion bodies. Before deciding on a new host proteins should be treated with 
glycoside hydrolases such as Galactosidase to identify existing glycosylation 
patterns. Host cells should be selected accordingly to ensure their ability to provide 
the necessary posttranslational modifications. 
The C-terminus of BACE1 has been shown by circular dichroism to have no 
significant secondary structural elements (R. Rose, in prep). However, there are 
cysteine residues in the area where the binding-site was proposed to be located. 
Covalent linkage between those residues could possibly bury or impede the binding-
site. The addition of the reducing agent DTT during the purification of GST-BACE1, 
however, did not induce binding to RTN3. Thus it remains questionable if disulfide 
bonds are relevant in the inhibition of protein-protein interaction. 
Another possible reason why interaction failed could be due to insufficient exposure 
of the binding sites. Although RTN3 was reduced to its terminal 40 amino acids, the 
number of amino acids may allow the generation of a secondary structure. However, 
a change in solvent conditions did not induce binding with BACE1 leaving it doubtful 
that binding sites could be uncovered by disrupting ionic or hydrophobic bonds. 
Accordingly, the MBP-tag is unlikely to manipulate the RTN3 binding-site as it is 
separated from RTN3 by a linker-domain and folds independently. To eliminate this 
in further studies it would be possible to cleave MBP from the fusion protein using the 
specific protease Factor Xa.  
A remaining question is the influence of MBP-RTN3 HD dimerisation observed on 
native gels. As mentioned before the majority of MBP-RTN3 HD is present in the 
form of a dimer, unless denaturing conditions are employed that would disrupt any 
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bonding between RTN3 and BACE1 as well. This raises the question whether 
dimerisation may possibly interfere with the RTN3-BACE1 binding-site. He et al. 
reported that C-terminally deleted RTN3 variants (minus 36 amino acids) lacking the 
QID motive were not able to bind BACE1 but would still form dimers with RTN3. It is 
therefore likely that dimerisation is mediated by a different region within the HD than 
binding to BACE1. However, a significant influence may still exist and further 
investigations are necessary to determine exactly which regions on RTN3 HD are 
responsible for dimerisation. 
5.7. Conclusion 
Due to time constraints it was not possible to investigate further and apply all of the 
mentioned amendments. Nevertheless, current data illustrates that the published 
interaction between RTN3 and BACE1 could be an artefact of the IP method and the 
indiscriminate use of detergents. It is evident that reconstitution of the proposed 
interaction between RTN3 and BACE1 using recombinant protein was not possible. 
Hence, it is essential to continue investigations and explore alternative strategies, 
such as the recombinant approach employed in this study. The challenging hunt for 
novel therapeutic approaches, in particular the modulation of BACE1 activity by 
protease inhibitors, has been demanding but promising so far. Any insights gained in 
function and distinctive features of RTN3 or BACE1 as well as being able to draw 
connections to AD pathogenesis might be more than valuable in the search for new 
small molecule therapeutics. 
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